(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
3 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 14.17%
Live Chart Being Loaded With Signals
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States...
Stats | |
---|---|
Dagens volum | 179 194 |
Gjennomsnittsvolum | 234 027 |
Markedsverdi | 81.26M |
EPS | €0 ( 2024-03-27 ) |
Neste inntjeningsdato | ( €-0.240 ) 2024-05-08 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -1.660 |
ATR14 | €0.0140 (1.03%) |
Volum Korrelasjon
Inflarx NV Korrelasjon
10 Mest negative korrelasjoner | |
---|---|
RMRM | -0.852 |
NVTS | -0.839 |
SFIX | -0.811 |
TRNS | -0.809 |
MBINO | -0.808 |
ABCM | -0.806 |
SKYW | -0.804 |
RVNC | -0.802 |
WPRT | -0.802 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Inflarx NV Korrelasjon - Valuta/Råvare
Inflarx NV Økonomi
Annual | 2023 |
Omsetning: | €61 795.00 |
Bruttogevinst: | €-957 050 (-1 548.75 %) |
EPS: | €-0.760 |
FY | 2023 |
Omsetning: | €61 795.00 |
Bruttogevinst: | €-957 050 (-1 548.75 %) |
EPS: | €-0.760 |
FY | 2022 |
Omsetning: | €0 |
Bruttogevinst: | €-585 852 (0.00 %) |
EPS: | €-0.610 |
FY | 2021 |
Omsetning: | €0.00 |
Bruttogevinst: | €0.00 (0.00 %) |
EPS: | €-1.100 |
Financial Reports:
No articles found.
Inflarx NV
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.